1180.0000 -22.30 (-1.85%)
NSE Apr 09, 2026 15:52 PM
Volume: 35,728
 

1180.00
-1.85%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Tatva Chintan Pharma Chem Ltd. is trading below its 100 day SMA of 1284.2
More from Tatva Chintan Pharma Chem Ltd.
Recommended